EICHORPublic-registry site landscape for NCT04710576, “A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)”, a Chronic Graft-versus-host-disease study sponsored by Syndax Pharmaceuticals. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT04710576 (registry record) |
| Study title | A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD) |
| Official title | AGAVE-201, A Phase 2, Open-label, Randomized, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Axatilimab at 3 Different Doses in Patients With Recurrent or Refractory Active Chronic Graft Versus Host Disease Who Have Received at Least 2 Lines of Systemic Therapy |
| Sponsor | Syndax Pharmaceuticals |
| Condition(s) | Chronic Graft-versus-host-disease |
| Phase | PHASE2 |
| Listed sites | 121 |
| Intervention(s) | Axatilimab |
| Site countries | United States, Australia, Belgium, Canada, France, Germany, Greece, Israel, Italy, Poland, Portugal, Singapore |
Patient-friendly overview of this study: eichor.com/study/NCT04710576.
Eichor generates a preliminary site-risk snapshot for NCT04710576 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
